Opinion|Videos|December 18, 2024
Treatment Response to PPAR Agonists and Other Therapies in PBC
Key Takeaways
- PBC involves autoimmune-mediated destruction of intrahepatic bile ducts by autoreactive T lymphocytes, leading to cholestasis.
- Accumulation of toxic bile acids due to cholestasis causes hepatocellular damage and inflammation.
The panel of experts discuss how to determine the effectiveness of treatment in primary biliary cholangitis (PBC), focusing on key clinical markers, biochemical responses, and patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you determine if treatment is effective in PBC?
Advertisement
Related to this article
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
52-Week Litifilimab Data in Cutaneous Lupus Erythematosus
3
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
4
Ratio of sTTR and NT-proBNP Change May Predict Treatment Results in ATTR-CM
5